Health
JCR Pharmaceuticals Presents Long-Term Clinical Data on Pabinafusp Alfa for the Treatment of Mucopolysaccharidosis Type II (MPS II) at ICIEM 2025
HYOGO, Japan, September 08, 2025--JCR announced that it presented new data from its pipeline of brain-penetrant enzyme replacement therapies at the 15th ICIEM 2025.
About this update from Jcr Pharmaceuticals Co., Ltd.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/5c2eb1e770484a162a4f6cacda3f8a41"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/0bXAYawSjTenpq2PtBrehQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/5c2eb1e770484a162a4f6cacda3f8a41","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/2yUH_9mw.VQsXa_tiYLMhw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0O2NmPXdlYnA-/https://media.zenfs.com/en/business-wire.com/5c2eb1e770484a162a4f6cacda3f8a41","width":1024,"height":512}},"lazy":false},{"type":"text","content":"– Oral Presentation Highlights Long-Term Neurocognitive Benefits of Pabinafusp Alfa for Patients with MPS II –","length":110,"tagName":"p","attribs":{}},{"type":"text","content":"– Additional Posters Underscore Broad Potential of J-Brain Cargo® Platform, Including Preclinical Data for Pabinafusp Alfa in MPS II and Nonclinical Data for JR-446 in MPS IIIB –","length":178,"tagName":"p","attribs":{}},{"type":"text","content":"HYOGO, Japan, September 08, 2025--(BUSINESS WIRE)--JCR Pharmaceuticals Co., Ltd. (TSE 4552; "JCR"), a global biopharmaceutical company dedicated to developing therapies for rare and genetic diseases, presented new data from its pipeline of brain-penetrant enzyme replacement therapies at the 15th International Congress of Inborn Errors of Metabolism (ICIEM) in Kyoto, Japan, held September 2-6, 2025. Key findings included five-year clinical data demonstrating sustained neurocognitive and somatic benefits of pabinafusp alfa (JR-141) in patients with mucopolysaccharidosis type II (MPS II, or Hunter syndrome), suggesting improvements in patients treated prior to significant neuronopathy and stabilization in those with advanced disease. Additional posters highlighted five years of safety data of pabinafusp alfa in MPS II, preclinical cardiovascular effects of pabinafusp alfa in MPS II, and nonclinical efficacy of JR-446, an investigational therapy for mucopolysaccharidosis type IIIB (MPS IIIB, also known as Sanfilippo syndrome type B).","length":1055,"tagName":"p"},{"type":"text","content":""The data presented at ICIEM add to the growing body of clinical evidence and real-...